Hiring requests from India’s healthcare and pharmaceutical sector rose 20% from April to September 2026 as companies shift from adding capacity to building capability and seek specialised talent in regulatory affairs, AI, and data-led R&D, according to a report by Spectrum Talent Management released on 17 October 2026.
Mid-career professionals accounted for 60% of demand, with those with 4 to 8 years of experience driving most hiring. Regulatory affairs, data analytics, AI and machine learning, operational excellence, complex generic R&D, supply chain and Global Capability Centres (GCCs) emerged as the key hiring drivers across pharmaceutical and life-sciences employers in India.
The hiring surge mirrors a strong policy push to invest in India’s pharmaceutical manufacturing and research base. The report said the Centre’s pharma Production-Linked Incentive (PLI) scheme has attracted Rs 46,744 crore in investments and created over 1.21 lakh jobs as of June 2026, while the bulk drugs scheme has commissioned 39 projects across 28 active pharmaceutical ingredients and key starting materials.
“Pharma and life sciences are moving from adding capacity to adding capability. Companies are increasingly using contract and flexible talent to meet these needs, while continuing to hire permanently for core roles,” said Atanu Banerjee, Chief Executive Officer, Spectrum Talent Management.
The shift reflects three structural changes in Indian pharma. First, large manufacturers and GCCs are investing in digital drug discovery, AI-led clinical research and advanced analytics, pushing demand for data and AI talent. Second, biosimilars, biologics, and complex generics require specialised R&D talent that is in short supply. Third, regulatory scrutiny from the US FDA, European and domestic agencies has made regulatory affairs and quality assurance senior-level priority hires.
Candidates with 4 to 8 years of experience, exposure to regulatory frameworks and hands-on work in analytics, AI or complex R&D are expected to command stronger pricing, faster offer cycles and better flexibility packages over the next two to three quarters.
The sector is also leaning harder on contract and flexi staffing to balance speed with cost. The report said this hybrid model, where permanent hires anchor core roles and contract talent accelerates specialised project work, is becoming the default operating model across pharmaceutical and life sciences employers.
With the PLI scheme and bulk drugs programme continuing to channel investment into capacity and capability, pharma’s talent story through FY27 is likely to remain defined by specialised, mid-career hiring rather than broad-based volume expansion.
